In a research report issued today, Maxim Group analyst Jason Mccarthy maintained a Buy rating on bluebird bio Inc (NASDAQ:BLUE) with a price …
Maxim’s healthcare analyst Jason Kolbert weighed in today with a favorable report on Galena Biopharma Inc (NASDAQ:GALE), after the company reported the presentation of two abstracts at …
Analysts are weighing in on IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), following the news that the FDA has provided the company with guidance regarding its abuse-deterrent Rexista …
IsoRay, Inc. (NYSEMKT:ISR) shares soared as much as 94 percent yesterday, after the company released data in an online publication regarding the first major peer reviewed …
Jason Kolbert of Maxim Group rates stocks in the biotechnology sector and he’s ranked #2811 out of 3602 analysts on TipRanks. Yesterday, Kolbert made two news …
Maxim Group’s healthcare analyst Jason Kolbert weighed in with a few insights on Athersys, Inc. (NASDAQ:ATHX), after the company held a comprehensive call with …
Maxim’s healthcare analyst Jason Kolbert weighed in with a few insights on Athersys, Inc. (NASDAQ:ATHX), after the company announced interim results from its exploratory Phase 2 clinical study …
Maxim Group lead analyst Nehal Chokshi came out with a special research report on Apple Inc. (NASDAQ:AAPL), initiating coverage with a Hold rating and a price target …
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), with a $2.
Maxim Group's healthcare analyst Jason Kolbert has high hopes for Gilead Sciences, Inc. (NASDAQ:GILD), reiterating a Buy recommendation on the stock with a 12-month price target of …
